Singapore markets closed
Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,136.08 -269.58 (-0.70%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.13 -2.90 (-0.04%) Bitcoin USD
59,748.55 -3,780.71 (-5.95%) CMC Crypto 200
1,286.15 -52.92 (-3.95%)
Newron Pharmaceuticals S.p.A. (0QOI.L)
LSE - LSE Delayed price. Currency in CHF
Add to watchlist
At close: 09:33AM BST
| Previous close | 7.28 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 4,223 |
| Market cap | 958,105 |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireNewron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Business WireData from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
Business WireNewron Presents 2023 Financial Results and Provides 2024 Outlook
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.
© 2024 Yahoo. All rights reserved.